Jonas Salk replied, "Well, the people I would say. There is no patent. Could you patent the sun?" The vaccine is calculated to be worth $7 billion had it been patented. However, lawyers from the National Foundation for Infantile Paralysis did look into the possibility of a patent, but ultimately determined that the vaccine was not a patentable invention because of prior art. Salk served on the board of directors of the John D. and Catherine T. MacArthur Foundation. Author Jon Cohen noted, "Jonas Salk made scientists and journalists alike go goofy. As one of the only living scientists whose face was
Remune P < 0.05 & HIV-1 lymphocyte proliferation P < 0.001 both favoring the Remune Group. The International AIDS Vaccine Research (IAVA) issued a report on “Whole Killed AIDS Vaccines” in 1999 reviewing a diverse aspect of the killed virus approach. Remune Remune is the first therapeutic HIV vaccine based on the killed whole virus approach. Remune was initially invented by Jonas Salk in 1987 and is now being developed by Immune Response BioPharma, Inc. (IRBP) Remune is a therapeutic HIV/AIDS vaccine that has completed over 25 clinical studies to date and shows a robust mechanism of action restoring white blood